Marina Chiara Garassino to Cetuximab
This is a "connection" page, showing publications Marina Chiara Garassino has written about Cetuximab.
Connection Strength
0.276
-
Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab? J Clin Oncol. 2008 May 20; 26(15):2600; author reply 2601-2.
Score: 0.078
-
Development and clinical indications of cetuximab. Int J Biol Markers. 2007 Jan-Mar; 22(1 Suppl 4):S40-6.
Score: 0.071
-
Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306. Ann Oncol. 2012 Oct; 23(10):2771-2772.
Score: 0.026
-
Role of cetuximab in the treatment of patients with NSCLC: are we throwing out the baby with the bath water? J Clin Oncol. 2010 Sep 20; 28(27):e467; author reply e468.
Score: 0.023
-
Cetuximab for metastatic colorectal cancer. N Engl J Med. 2009 Jul 02; 361(1):95; author reply 96-7.
Score: 0.021
-
Cetuximab for colorectal cancer. N Engl J Med. 2008 Mar 13; 358(11):1196; author reply 1196-7.
Score: 0.019
-
Predicting response of molecular targeted therapies: a still possible challenge? Ann Oncol. 2008 May; 19(5):829-30.
Score: 0.019
-
Response of thymoma to cetuximab. Lancet Oncol. 2007 May; 8(5):449-50.
Score: 0.018